NXTC NextCure, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1661059 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY29.4%
TTM EPS YoY71.5%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-281.1%
ROA-166.2%
ROIC (approx.)-505.2%
Asset turnover—
Leverage & solvency
Liabilities / assets43.3%
Debt / equity0.00x
Current ratio2.31x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.04x
Accruals ratio7.4%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $4.54M | $7.42M | $6.83M | $6.80M | $6.14M | $24.09M | $7.90M | $8.90M |
| SG&A expense | $4.43M | $2.59M | $3.27M | $2.96M | $2.81M | $3.20M | $3.73M | $3.55M |
| Operating income | -$6.92M | -$15.09M | -$10.11M | -$9.76M | -$8.95M | -$27.29M | -$11.62M | -$12.46M |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | — |
| Net income | -$6.85M | -$14.89M | -$9.80M | -$9.44M | -$8.62M | -$26.81M | -$10.98M | -$11.60M |
| EPS (basic) | -1.29 | -2.80 | -1.87 | — | -3.22 | -11.29 | -4.70 | — |
| EPS (diluted) | -1.29 | -2.80 | -1.87 | — | -3.22 | -11.29 | -4.70 | — |
| Weighted avg. shares (diluted) | 5.31M | 5.31M | 5.24M | — | 2.68M | 2.37M | 2.33M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $8.73M | $15.26M | $15.17M | $25.98M | $7.32M | $4.89M | $21.83M | $27.73M |
| Current assets | $9.70M | $22.25M | $31.74M | $43.75M | $32.64M | $40.02M | $58.90M | $71.81M |
| PP&E, net | — | $283,000 | $2.99M | $3.27M | $3.64M | $4.17M | $4.80M | $5.46M |
| Total assets | $9.70M | $22.62M | $37.98M | $50.18M | $39.61M | $47.69M | $67.14M | $80.86M |
| Current liabilities | $4.20M | $6.41M | $6.89M | $10.57M | $10.99M | $10.78M | $5.74M | $9.57M |
| Total liabilities | $4.20M | $10.47M | $11.26M | $15.24M | $15.97M | $16.04M | $11.28M | $15.39M |
| Shareholders' equity | $5.50M | $12.15M | $26.72M | $34.94M | $23.65M | $29.65M | $55.85M | $65.47M |
| Shares outstanding | 4.58M | 4.07M | 3.61M | 3.51M | 2.68M | 2.34M | 28.01M | 2.33M |
| Cash flow statement | ||||||||
| Operating cash flow | -$12.07M | -$9.71M | -$13.36M | -$7.64M | -$6.27M | -$22.71M | -$12.99M | -$6.97M |
| Capital expenditure | — | — | — | — | — | — | — | -$34,000 |
| Free cash flow | — | — | — | — | — | — | — | -$6.93M |
| Investing cash flow | $5.54M | $9.79M | $1.30M | $6.00M | $8.70M | $3.76M | $7.09M | $6.96M |
| Financing cash flow | $1,000 | $22,000 | $1.25M | $20.29M | $0 | — | — | $36,000 |
| Stock-based compensation | $196,000 | $304,000 | $344,000 | $435,000 | $600,000 | $587,000 | $1.36M | $1.52M |
Free plan shows the latest 8 periods; Pro shows all 35 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.